Tiger Pharmaceuticals (03347): Intended to participate in the privatization and sale of assets of the subsidiary Fangda Holdings

Zhitongcaijing · 6d ago

Zhitong Finance App News, Tiger Pharmaceuticals (03347) issued an announcement. Based on the company's strategic development and business layout needs, in order to further focus on the main clinical CRO business, optimize resource allocation and operational decision-making efficiency, enhance the company's core competitiveness and create value for all shareholders, the company plans to sell control of its subsidiary Fangda Holdings and divest the overseas laboratory business of Fangda Holdings.

The deal consists of two parts: privatization and spin-off. The company's wholly-owned subsidiaries Hong Kong Tiger, CRL, Dr. Li Song and their related trusts jointly funded the establishment of SanRex, and used SanRex as the acquirer to privatize Fangda Holdings, a holding subsidiary of the company listed on the Hong Kong Stock Exchange in a planned arrangement. After the privatization is completed, Fangda Holdings will become a wholly-owned subsidiary of SanRex.

As part of this transaction, the parties will carry out a spin-off transaction for Fangda Holdings, including asset restructuring, equity adjustments, and share transfers. After the asset restructuring was completed, the shareholding ratios of CRL, Dr. Li Song and his related trusts, and Hong Kong Tiger at the SanRex level were adjusted so that the shareholding ratio of CRL, Dr. Li Song and its related trusts, and Hong Kong Tiger at the SanRex level was consistent with the share value ratio of the target business, non-target business outside of China, and non-target business within China on the day of delivery, respectively. After the transaction was completed, SanRex retained only the target business, and the target business was eventually held by CRL. Non-target business outside of China was sold to Frontage ACE through equity allocation, and non-target business in China was retained by Hong Kong Tiger through equity allocation.

According to the “Transaction Agreement” signed by the parties, based on commercial considerations and agreement between the parties, the initial transaction price for the target business is US$470 million, the initial transaction price for the non-target business outside of China is US$804.4 million, and the initial transaction price for the non-target business within China will be US$205.5 million. The final transaction price will be paid according to the estimated amount at the time of delivery according to the price adjustment mechanism agreed in the “Transaction Agreement”, and adjusted and settled according to the delivery statement prepared within 120 days after delivery.

Prior to this transaction, the company held a total of 64.48% of Fangda Holdings shares; after the transaction is completed, the company will no longer hold Fangda Holdings shares and will only retain non-target business in China.

The company expects to receive cash consideration of HK$536 million (before tax and related expenses) corresponding to the cancellation of 11.09% of Fangda Holdings directly held by the company during the privatization phase.

After the privatization is completed, Hong Kong Tiger, a wholly-owned subsidiary of the company, will divest target businesses and non-target businesses outside of China (excluding Acme Bioscience, Inc.) through equity adjustments and equity transfers at the SanRex level. Hong Kong Tiger is expected to further obtain cash consideration for SanRex's equity adjustments. The specific consideration amount is affected by the final transaction price of the relevant asset and needs to be finalized in conjunction with the adjustments made according to the delivery statement.

In addition to the above consideration, this transaction establishes a performance reward mechanism. If the target business achieves the performance targets in 2026 and 2027 operating income and adjusted EBITDA profit margins, the company and Hong Kong Tiger will receive corresponding performance rewards as privatization plan shareholders on the date of registration of the privatization plan.